HOLOGIC INC: The Company Has Been Taken Private

1. What happened?

Hologic, Inc. (ticker: HOLX) is no longer a public company. On April 7, 2026, an investment group backed by Blackstone and TPG acquired the company for $17.3 billion. This price was 22% higher than the stock’s closing price the day before the deal was announced. If you owned shares, they were automatically converted into $76.00 in cash per share. You also received a "Contingent Value Right" (CVR), which gives you a chance to earn up to $2.50 more per share if the company hits specific revenue goals for its diagnostics and breast health businesses over the next two years.

2. Why did it happen?

Hologic moved from public to private to focus on long-term growth rather than quarterly results. As a public company, Hologic faced pressure to meet short-term profit goals. Now, the company aims to expand its diagnostics business and integrate its breast health technology without the stock price volatility associated with public market expectations.

3. Who is in charge now?

The acquisition triggered a major leadership change. The previous Board of Directors resigned, and former CEO Stephen P. MacMillan stepped down. José (Joe) E. Almeida is the new CEO, with a mandate to streamline operations and manage the company’s $3.2 billion debt. The company also adopted new rules that give a five-member board, controlled by Blackstone and TPG, full control over major decisions.

4. Why does this matter?

• For Investors: The "HOLX" ticker is gone from the Nasdaq. You cannot trade this stock anymore. The $76.00 per share is your final payout. The CVR is not a tradable stock; it simply tracks whether the company hits a $5.2 billion revenue target in 2027.
• For the Market: Hologic no longer files public financial reports with the SEC. This means the company’s data on women’s health and diagnostics will no longer be available to the public.
• For the Business: The company used the acquisition funds to pay off $2.8 billion in high-interest debt and centralized power with its new private equity owners.

5. What should you do now?

• Check your account: Your broker should have converted your shares into the $76.00 cash payment. If you don't see the funds, contact your brokerage’s corporate actions department.
• Watch for the CVR: Keep an eye on any mail or emails regarding your "Contingent Value Right." Equiniti Trust Company manages this. If the company hits its revenue targets, any future payout will go directly to the registered holders of these rights.
• Reallocate your capital: Since you cannot trade Hologic anymore, you may want to look at other opportunities in the medical diagnostics space. Companies like Danaher (DHR), Thermo Fisher Scientific (TMO), or QuidelOrtho (QDEL) remain active in the public markets if you are looking to maintain exposure to this sector.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and should not be considered investment advice. Always do your own research before making financial decisions.